Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically)

scientific article

Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically) is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1002/14651858.CD007578.PUB2
P698PubMed publication ID21412905

P2093author name stringMichael Taylor
Rebecca Ryan
Kelly Allen
Sophie Hill
Cathy Mead
Dianne Lowe
P2860cites workNotification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) through medical treatment (iatrogenically)Q24242392
Methods of communicating a primary diagnosis of breast cancer to patientsQ24244055
Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the USQ24288772
The reporting of theoretical health risks by the media: Canadian newspaper reporting of potential blood transmission of Creutzfeldt-Jakob diseaseQ24807265
Methods for the thematic synthesis of qualitative research in systematic reviewsQ29618082
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care SettingsQ29619731
Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard?Q30230440
Variant Creutzfeldt-Jakob disease: a cause for concern. Review of the evidence for risk of transmission through abdominal lymphoreticular tissue surgery.Q31168115
The expanding universe of prion diseasesQ33239695
Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002.Q33263263
Methods for the synthesis of qualitative research: a critical reviewQ33492573
Variant Creutzfeldt Jakob DiseaseQ34056300
Creutzfeldt-Jakob disease: the problem of recipient notificationQ34077606
Creutzfeldt-Jakob disease: blood infectivity and screening testsQ34422601
Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapiesQ34489473
Ethical analysis of communicating the risk of iatrogenic Creutzfeldt-Jakob diseaseQ49134178
The mad cow problem in the UK: risk perceptions, risk management, and health policy development.Q50161938
Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusionQ50193994
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Q51037857
An investigation of potential neurosurgical transmission of Creutzfeldt-Jakob disease: challenges and lessons learned.Q51249039
Problems with disposable laryngoscope blades.Q51302622
Collaborative infection control policies for anaesthetic equipment are needed.Q51341139
Risk factors for sporadic Creutzfeldt-Jakob disease.Q53031206
An innovative, inclusive process for meso-level health policy development.Q53180859
Intersecting discourses: MMR vaccine and BSE.Q53292756
British MRC reprimanded over clinical test record.Q53573513
Prion diseases and dental treatment: principles and practice of patients with/suspected or at-risk of CJD: case reports.Q53916657
The HIV information project for transfusion recipients a decade after transfusion.Q54598459
Peer-Reviewed Articles and Public HealthQ56346039
Uncertainty and significanceQ57112490
From alcohol and breast cancer to beef and BSE--improving our communication of riskQ57241670
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedyQ57301966
BSE in human tissue fires debate on patient disclosureQ59032179
Consensus conference on vCJD screening of blood donors: report of the panelQ59465666
Brussels inquiry criticizes BSE secrecyQ60089074
Quarterly communicable disease review. April to June 2001.Q34549531
The prion theory: background and basic informationQ34582147
Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectivesQ34636936
The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene testQ34680311
Mechanical design of a shape memory alloy actuated prosthetic handQ34704724
Sterilization issues in vCJD--towards a consensus: meeting between the Central Sterilizing Club and Hospital Infection Society. 12th September 2000.Q34812377
Desired elements of HIV testing services: test recipient perspectivesQ35039273
Communication, information and support for adults with malignant cerebral glioma : a systematic literature reviewQ35045010
How to formulate research recommendationsQ35082894
Risk communication of the transmissible spongiform encephalopathiesQ35148252
Ethical considerations in presymptomatic testing for variant CJD.Q35428275
Acquired prion disease: iatrogenic CJD, variant CJD, kuruQ35549020
vCJD screening and its implications for transfusion - strategies for the future?Q35563651
Managing recalls and withdrawals of blood componentsQ35613182
A review of general hepatitis C virus lookbacks in CanadaQ35675883
Creutzfeldt-Jakob disease following corneal transplantationQ35751022
Informed consent for blood transfusion: should the possibility of prion risk be included?Q35833537
Communicating with patients about medical errors: a review of the literatureQ35859667
Joint ASH and AABB educational sessionQ35961850
Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccinationQ36037149
How can doctors communicate information about risk more effectively?Q36037213
Mad cow disease and vCJD: understanding the risksQ36038404
Care management of Creutzfeldt-Jakob Disease within the United KingdomQ36048676
No clinical evidence of hidden vCJD in UK childrenQ36153081
Communicating prognosis in cancer care: a systematic review of the literatureQ36154086
Developing an administrative plan for transfusion medicine--a global perspectiveQ36266564
Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.Q36302930
Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experienceQ36381542
Discussing bad news in the outpatient oncology clinic: rethinking current communication guidelinesQ36381835
A patient's perspective on hemophiliaQ36456673
Public health and civil liberties. Introduction to the talking point on public health versus civil libertiesQ36495086
Creutzfeldt-Jakob disease: a rare cause of dementia in elderly personsQ36521408
Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review studyQ36588347
Decontamination and CJD: the latest guidanceQ36670760
Empty systematic reviews: hidden perils and lessons learnedQ36817449
Response to paper by Lang A, Edwards N, and Fleiszer A.Q36817453
Halting the spread of human prion disease--exceptional measures for an exceptional problemQ36836191
The epidemiology of Creutzfeldt-Jakob disease in Canada: a review of mortality dataQ36857133
An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma productsQ37307945
What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare.Q37332504
Breaking bad news. 2: What evidence is available to guide clinicians?Q38550704
Science, uncertainty and policy: food for thoughtQ38703116
Public understanding of food risks in four European countries: a qualitative studyQ39032058
Is surgery a risk factor for Creutzfeldt-Jakob disease? Outcome variation by control choice and exposure assessmentsQ40126129
Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.Q40305663
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies.Q40483672
Future counselling of donors and recipients of blood products concerning prion-related diseasesQ40567812
Knowledge, attitude, and behavior of students regarding 'mad cow disease'.Q40573579
Creutzfeldt-Jakob disease and infection controlQ40664868
Health communication and consumer behavior on meat in Belgium: from BSE until dioxinQ40767195
Surveillance of blood transfusion safety: contribution of the hemovigilance strategy in FranceQ41753407
Patients informed of increased risk of vCJD contactQ42404954
A new human genotype prone to variant Creutzfeldt-Jakob diseaseQ42530495
Monitoring Creutzfeldt-Jakob diseaseQ42763284
Victims of Creutzfeldt-Jakob diseaseQ42763739
The politics of risk: the case of BSE. If we want less paternalism we must first educate ourselvesQ42769043
Communicating risksQ42948885
Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992.Q43035681
Recipients of blood or blood products "at vCJD risk".Q43124338
Creutzfeldt-Jakob disease after pituitary gonadotrophinsQ43152098
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy... but members of the public make up their own minds about risksQ43180220
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Scientists who inflame public anxieties must share responsibility for resulting panicQ43187765
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Doctors and scientists must be able to communicate degree of risk...Q43187789
Bovine spongiform encephalopathy. Study shows need for better communication between government and doctorsQ43190287
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and CanadaQ43218822
International case studies of psychosocial ripple effects of bovine spongiform encephalopathy (BSE) in European countriesQ43565202
Policy understanding of science, public trust and the BSE-CJD crisis.Q44011663
Good and bad news about transmissible spongiform encephalopathies (prion diseases).Q44068517
Creutzfeld-Jakob disease: recommendations for infection control.Q44921979
Prions and haemophilia: assessment of riskQ45855088
Dental treatment of a patient in the new 'at-risk' category for CJD.Q45875887
Genomics and blood substitutes for 21st century Europe ("EuroBloodSubstitutes").Q46773050
Proceedings of a consensus conference: the screening of blood donors for variant CJD.Q47808189
Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.Q48340913
The spongiform encephalopathies: prion diseases.Q48350306
Transplantation of ocular tissue from a donor with sporadic Creutzfeldt-Jakob diseaseQ48422321
"On a supposed right to lie [to the public] from benevolent motives": communicating health risks to the publicQ48686947
Percutaneous tracheostomy and Creutzfeldt-Jakob DiseaseQ48875709
Some ethical ground rules for BSE and other public health threatsQ48933321
Bovine spongiform encephalopathy (BSE): the ethics concerning decisions about whether to continue taking a risk with this diseaseQ48933332
Blood contamination of the laryngeal mask airways and laryngoscopes--what do we tell our patients?Q49125256
BSE meeting reflects growing distrust of expert panelsQ60089325
Patients' and family members' experiences of open disclosure following adverse eventsQ60806370
Listening to patients with rare diseasesQ64043947
Bovine Spongiform Encephalopathy and Related Agents: Risk Factors of Biological Products. An Informal Consultation/Working MeetingQ68331192
Creutzfeldt-Jakob diseaseQ70811575
Getting the message acrossQ71286418
Pooled plasma derivatives and Creutzfeldt-Jakob diseaseQ71520229
Variant Creutzfeldt-Jakob disease in UK children: a national surveillance studyQ73176027
Creutzfeldt-Jakob disease and eye surgery--new disease, old diseaseQ73245965
The BSE inquiry and communication of riskQ73478341
BSE reportQ73519221
vCJD: broad U.S. response requiredQ73602250
Breaking bad news about cancer: patients' preferences for communicationQ73703066
Transfusion medicine and spongiform encephalopathyQ73794148
Controlling new prion diseasesQ73890310
[The precaution principle and blood transfusion]Q74086100
Department of Health withdraws variant CJD transmission recommendations for single-use instrumentsQ74218887
United Nations addressQ74286892
Prevention of Creutzfeldt-Jakob disease in health care workers: a case studyQ74315452
CJD updateQ74336288
Communication of risk: choice, consent, and trustQ74484476
Infectious diseases. First U.S. case of mad cow sharpens debate over testingQ75236334
[Development of public health law: valuable elements worth sharing]Q76323444
[A screening questionnaire for determining risk of Creuzfeldt-Jacob disease transmission during ophthalmic examination]Q76341769
Potential Creutzfeldt-Jakob disease (CJD) exposure: to notify or not to notifyQ77141810
Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART). Quantification of risks as part of informed consentQ77309520
Hepatitis C update: implications of the blood transfusion "lookback"Q77400968
Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathiesQ77738553
Creutzfeldt-Jakob disease targeted lookbackQ77770301
HIV Testing And Counseling: Test Providers' Experiences of Best PracticesQ79094523
The CJD mysteryQ79131508
Variant Creutzfeldt-Jacob disease - the availability of a screening test will be the beginning, not the end, of difficult transfusion-related issuesQ79279401
[Transfusion risk analysis with regard to vCJD in France]Q79450767
Implications of notifying donors and recipientsQ80226808
Long-term survival after blood transfusion: a population based study in the North of EnglandQ80260178
Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological featuresQ80508289
French doctors on trial for manslaughterQ80773835
6 Years of shot reporting--its influence on UK blood safetyQ80900269
Informed consent for creutzfeldt-jakob disease after corneal transplantationQ81158992
Fighting the good fight in EuropeQ81180265
Questionnaire to reduce the risk of iatrogenic prion disease transmissionQ81819380
Disclosing medical errors to patients: a challenge for health care professionals and institutionsQ84409392
MinervaQ93606658
Variant Creutzfeldt-Jakob disease: costs borne by familiesQ95801859
The HRT story: lessons for epidemiologistsQ95814736
P921main subjectprion protein familyQ24724413
Creutzfeldt-Jakob diseaseQ49989
P577publication date2011-03-16
P1433published inCochrane Database of Systematic ReviewsQ15750361
P1476titleNotification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically)